COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05603052

Collin Choi

collin.choi@eubiologics.com

2022-11-02

Recruiting

RCT

Randomized

Parallel

Blind label

single-center

Prevention

inclusion criteria: individuals aged 18 years and older who voluntarily decide to participate in this study and provide written informed consent female of childbearing potential who agree to use medically allowed methods of contraception during the study period individuals who agrees not to perform blood donation and transfusion during the study period

individual being considered to be confirmed covid-19 direct contact with covid-19 infected person within 14 days prior to the 1st dose of the ip individuals at high risk of exposure to sars-cov-2 individuals with clinically significant abnormalities in clinical laboratory tests, ecgs, and chest x-ray during screening individuals with fever within 72 hours prior to the 1st dose of the ip or suspected other infectious disease or symptoms associated with other infectious disease individuals with serious medical or psychiatric disease history of sars-cov or mers-cov infection history of allergic reaction or hypersensitivity reactions to any of components of the ip history of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination history of receiving organ or bone marrow transplant suspected or history of drug abuse or alcohol abuse within 6 months prior to vaccination history of vaccination against sars-cov, mers-cov, or sars-cov-2 history of vaccination with test vaccine substance treatment with immunosuppressants or immune modifying drugs history of treatment with antipsychotics or opioid dependence pregnant or lactating women other reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator

4

EuBiologics Co.,Ltd

18

100

Congo;The Democratic Republic of the

Healthy volunteers

N/A

4000

The difference in neutralizing antibody SRR of EuCorVac-19 and ChAdOx1;The proportion of GMT of neutralizing antibody of EuCorVac-19 and ChAdOx1

None

Phase 3

[{"arm_notes": "nan", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "nan", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "nan", "treatment_id": 486, "treatment_name": "Eucorvac-19", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "nan", "treatment_id": 486, "treatment_name": "Eucorvac-19", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]